U.S. markets close in 3 hours 33 minutes
  • S&P 500

    4,381.97
    -40.33 (-0.91%)
     
  • Dow 30

    34,929.63
    -214.68 (-0.61%)
     
  • Nasdaq

    14,568.05
    -272.67 (-1.84%)
     
  • Russell 2000

    2,179.48
    -37.45 (-1.69%)
     
  • Crude Oil

    71.52
    -0.39 (-0.54%)
     
  • Gold

    1,798.80
    -0.40 (-0.02%)
     
  • Silver

    24.57
    -0.75 (-2.97%)
     
  • EUR/USD

    1.1833
    +0.0025 (+0.21%)
     
  • 10-Yr Bond

    1.2390
    -0.0370 (-2.90%)
     
  • GBP/USD

    1.3882
    +0.0058 (+0.42%)
     
  • USD/JPY

    109.6210
    -0.7540 (-0.68%)
     
  • BTC-USD

    37,736.08
    -1,235.82 (-3.17%)
     
  • CMC Crypto 200

    894.34
    +18.11 (+2.07%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful?

·5 min read

Every investor in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

Y-mAbs Therapeutics isn't enormous, but it's not particularly small either. It has a market capitalization of US$1.6b, which means it would generally expect to see some institutions on the share registry. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Y-mAbs Therapeutics.

See our latest analysis for Y-mAbs Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Y-mAbs Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Y-mAbs Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Y-mAbs Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Y-mAbs Therapeutics. Wg Biotech Aps is currently the largest shareholder, with 13% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.4% and 6.4%, of the shares outstanding, respectively.

On further inspection, we found that more than half the company's shares are owned by the top 8 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Y-mAbs Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Y-mAbs Therapeutics, Inc.. Insiders own US$264m worth of shares in the US$1.6b company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.

General Public Ownership

With a 10% ownership, the general public have some degree of sway over Y-mAbs Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 11% stake in Y-mAbs Therapeutics. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Private Company Ownership

We can see that Private Companies own 14%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 5 warning signs for Y-mAbs Therapeutics you should be aware of, and 1 of them is potentially serious.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.